HORSHAM, Pa.--(BUSINESS WIRE)--TargetRx Inc. today announced that the company has received $9.6M of venture funding led by existing investors Quaker BioVentures, New Enterprise Associates (NEA) and Domain Associates. This infusion of capital will further support the company’s plans for growth and the development of innovative new products designed to help the pharmaceutical industry improve sales and marketing effectiveness as well as drive overall business performance.
